A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

May 31, 2015

Study Completion Date

June 30, 2015

Conditions
Liver CirrhosisHepatic CirrhosisPortal Hypertension
Interventions
DRUG

IDN-6556

25 mg BID

Trial Locations (16)

10016

New York University Lagone Medical Center, New York

11030

North Shore University Hospital, Manhasset

19104

University of Pennsylvania, Philadelphia

19141

Albert Einstein Medical Center, Philadelphia

20016

Johns Hopkins Sibley Memorial Hospital, Washington D.C.

21287

Johns Hopkins Hospital, Baltimore

23226

Bon Secours St. Mary's Hospital, Richmond

23249

McGuire DVAMC, Richmond

23602

Bon Secours Mary Immaculate Hospital, Newport News

33136

University of Miami, Miami

39216

University of Mississippi Medical Center, Jackson

77030

St. Luke's Health Baylor College of Medicine, Houston

University of Texas Health Science Center at Houston, Houston

84132

University of Utah Hospital, Salt Lake City

06516

VA Connecticut Healthcare System, West Haven

07103

Rutgers New Jersey Medical School, Newark

Sponsors
All Listed Sponsors
lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT02230683 - A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension | Biotech Hunter | Biotech Hunter